NEW YORK (GenomeWeb News) – Vermillion said in a US Securities and Exchange Commission filing released after the close of the market yesterday that its shareholders elected Robert Goggin to the company's board of directors at the firm's annual meeting last week.

Goggin, who was put forth as a candidate by a trio of dissident shareholders comprising himself, Gregory Novak, and George Bessenyei, defeated Vermillion's candidate, Roberta Della Vedova, with 4,749,042 votes cast for Goggin compared to 3,938,399 for Vedova.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: GWAS links gene to noise-induced hearing loss in mice, population genetics of malaria parasites, and more.

Nautilus' Alexandra Ossola examines how Tay-Sachs disease jump-started the genetic disease testing field.

FASEB says guidelines proposed by the NIH to bolster research reproducibility are premature and don't take the full range of scientific studies into consideration.

Liquid biopsies and DNA tests may be able to tell physicians whether a cancer patient is relapsing, the New York Times reports.